Legal Settlements and Loss Contingencies	6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: In the second quarter of 2026, Teva recorded expenses of $230 million in legal settlements and loss contingencies, compared to expenses of $166 million in the second quarter of 2025. Expenses in the second quarter of 2026 were mainly related to an estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) . Expenses in the second quarter of 2025 were mainly related to an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), and a provision recorded in connection with the antitrust litigation related to QVAR ® . See note 10. In the first six months of 2026, Teva recorded expenses of $303 million in legal settlements and loss contingencies, compared to $252 million in the first six months of 2025. Expenses in the first six months of 2026 were mainly related to an estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the first six months of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, and a provision recorded in connection with the antitrust litigation related to QVAR. See note 10. As of June 30, 2026 and December 31, 2025, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,854 million and $4,753 million, respectively.

In the second quarter of 2026, Teva recorded expenses of $230 million in legal settlements and loss contingencies, compared to expenses of $166 million in the second quarter of 2025.

Expenses in the second quarter of 2026 were mainly related to an estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments)

. Expenses in the second quarter of 2025 were mainly related to an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), and a provision recorded in connection with the antitrust litigation related to QVAR

. See note 10.

In the first six months of 2026, Teva recorded expenses of $303 million in legal settlements and loss contingencies, compared to $252

million in the first six months of 2025. Expenses in the first six months of 2026 were mainly related to an estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the first six months of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, and a provision recorded in connection with the antitrust litigation related to QVAR. See note 10.

As of June 30, 2026 and December 31, 2025, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,854 million and $4,753 million, respectively.